Anti-NF-kB p65 (phospho S529) antibody (ab84333)
Key features and details
- Rabbit polyclonal to NF-kB p65 (phospho S529)
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-NF-kB p65 (phospho S529) antibody
See all NF-kB p65 primary antibodies -
Description
Rabbit polyclonal to NF-kB p65 (phospho S529) -
Host species
Rabbit -
Tested Applications & Species
See all applications and species dataApplication Species WB Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
(Peptide available asab101479) -
Positive control
- This antibody gave a positive signal in the following whole cell lysates: HeLa; HeLa Nuclear; A431.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituent: PBS
Batches of this product that have a concentrationConcentration information loading...
Purity
70 - 90% by HPLCClonality
PolyclonalIsotype
IgGResearch areas
Associated products
-
Compatible Secondaries
-
Immunizing Peptide (Blocking)
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab84333 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
GuaranteedTested applications are guaranteed to work and covered by our Abpromise guarantee.
PredictedPredicted to work for this combination of applications and species but not guaranteed.
IncompatibleDoes not work for this combination of applications and species.
Application Species WB HumanAll applications ChimpanzeeMacaque monkeyGorillaOrangutanApplication Abreviews Notes WB Use a concentration of 1 µg/ml. Detects a band of approximately 56 kDa (predicted molecular weight: 60 kDa).Notes WB
Use a concentration of 1 µg/ml. Detects a band of approximately 56 kDa (predicted molecular weight: 60 kDa).Target
-
Function
NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. -
Sequence similarities
Contains 1 RHD (Rel-like) domain. -
Domain
the 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors. -
Post-translational
modificationsUbiquitinated, leading to its proteasomal degradation. Degradation is required for termination of NF-kappa-B response.
Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes the formation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity. Phosphorylation at Ser-311 disrupts the interaction with EHMT1 without preventing monomethylation at Lys-310 and relieves the repression of target genes.
Phosphorylation at Ser-311 disrupts the interaction with EHMT1 and promotes transcription factor activity (By similarity). Phosphorylation on Ser-536 stimulates acetylation on Lys-310 and interaction with CBP; the phosphorylated and acetylated forms show enhanced transcriptional activity.
Reversibly acetylated; the acetylation seems to be mediated by CBP, the deacetylation by HDAC3. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA. Acetylation at Lys-310 is required for full transcriptional activity in the absence of effects on DNA binding and NFKBIA association. Acetylation can also lower DNA-binding and results in nuclear export. Interaction with BRMS1 promotes deacetylation of 'Lys-310'. -
Cellular localization
Nucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B). Colocalized with RELA in the nucleus upon TNF-alpha induction. - Information by UniProt
-
Database links
- Entrez Gene: 466665 Chimpanzee
- Entrez Gene: 101150285 Gorilla
- Entrez Gene: 5970 Human
- Entrez Gene: 100456049 Orangutan
- Omim: 164014 Human
- SwissProt: Q04206 Human
- Unigene: 502875 Human
-
Alternative names
- Avian reticuloendotheliosis viral (v rel) oncogene homolog A antibody
- MGC131774 antibody
- NF kappa B p65delta3 antibody
see all
Images
-
All lanes : Anti-NF-kB p65 (phospho S529) antibody (ab84333) at 1 µg/ml
Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate with NF-kB p65 peptide (ab116684)
Lane 2 : HeLa (Human epithelial carcinoma cell line) Nuclear Lysate with NF-kB p65 peptide (ab116684)
Lane 3 : A431 (Human epithelial carcinoma cell line) Whole Cell Lysate with NF-kB p65 peptide (ab116684)
Lane 4 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate withHuman NF-kB p65 (phospho S529) peptide (ab101479)
Lane 5 : HeLa (Human epithelial carcinoma cell line) Nuclear Lysate withHuman NF-kB p65 (phospho S529) peptide (ab101479)
Lane 6 : A431 (Human epithelial carcinoma cell line) Whole Cell Lysate withHuman NF-kB p65 (phospho S529) peptide (ab101479)
Lysates/proteins at 10 µg per lane.
Blocking peptides at 1 µg/ml per lane.
Secondary
All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 60 kDa
Observed band size: 56 kDa why is the actual band size different from the predicted?
Exposure time: 20 minutes
Datasheets and documents
References (0)
ab84333 has not yet been referenced specifically in any publications.
Images
-
All lanes : Anti-NF-kB p65 (phospho S529) antibody (ab84333) at 1 µg/ml
Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate with NF-kB p65 peptide (ab116684)
Lane 2 : HeLa (Human epithelial carcinoma cell line) Nuclear Lysate with NF-kB p65 peptide (ab116684)
Lane 3 : A431 (Human epithelial carcinoma cell line) Whole Cell Lysate with NF-kB p65 peptide (ab116684)
Lane 4 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate withHuman NF-kB p65 (phospho S529) peptide (ab101479)
Lane 5 : HeLa (Human epithelial carcinoma cell line) Nuclear Lysate withHuman NF-kB p65 (phospho S529) peptide (ab101479)
Lane 6 : A431 (Human epithelial carcinoma cell line) Whole Cell Lysate withHuman NF-kB p65 (phospho S529) peptide (ab101479)
Lysates/proteins at 10 µg per lane.
Blocking peptides at 1 µg/ml per lane.
Secondary
All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 60 kDa
Observed band size: 56 kDa why is the actual band size different from the predicted?
Exposure time: 20 minutes